Sangamo Therapeutics, Inc. (SGMO)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Sangamo Therapeutics, Inc. (SGMO) is down 49.1% since the beginning of the year. At $0 per share, SGMO is trading 72.1% below its 52-week high of $1. Investors who bought $1,000 worth of SGMO shares 5 years ago would now be looking at an investment worth $20.

Sangamo Therapeutics, Inc. (SGMO) has returned -49.05% so far this year and -54.75% over the past 12 months. Over the last ten years, SGMO has returned -29.51% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.

Based on dividend-adjusted daily data since Apr 6, 2000, SGMO's average daily return is +0.10%, while the average monthly return is +2.21%. At this rate, an investment would double in approximately 2.6 years.

Historically, 48% of months were positive and 52% were negative. The best month was Jun 2000 with a return of +317.1%, while the worst month was Nov 2008 at -68.5%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 9 months.

On a daily basis, SGMO closed higher 47% of trading days. The best single day was May 11, 2017 with a return of +60.9%, while the worst single day was Nov 11, 2008 at -65.5%.

Sangamo Therapeutics, Inc. has an annualized alpha of 12.65%, beta of 1.55, and R2 of 0.11 versus S&P 500 Index. Calculated based on daily prices since April 07, 2000.

• This stock participated in 211.36% of S&P 500 Index downside but only 206.41% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.11 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

SGMO ranks 22 for risk / return — below 22% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Sangamo Therapeutics, Inc. (SGMO) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Sangamo Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Sangamo Therapeutics, Inc. was 99.80%, occurring on May 7, 2026. The portfolio has not yet recovered.

The current Sangamo Therapeutics, Inc. drawdown is 99.57%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Sangamo Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Sangamo Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.